52 related articles for article (PubMed ID: 20528318)
1. Cost-effectiveness and impact on quality of life of alefacept in the treatment of psoriasis.
Scheinfeld N; Parish D
Expert Rev Pharmacoecon Outcomes Res; 2007 Dec; 7(6):545-57. PubMed ID: 20528318
[TBL] [Abstract][Full Text] [Related]
2. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
Scheinfeld N
J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
[TBL] [Abstract][Full Text] [Related]
3. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.
Staidle JP; Dabade TS; Feldman SR
Expert Opin Pharmacother; 2011 Sep; 12(13):2041-54. PubMed ID: 21736530
[TBL] [Abstract][Full Text] [Related]
4. The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
Langewouters AM; Van Erp PE; De Jong EM; Van De Kerkhof PC
J Dermatolog Treat; 2006; 17(6):362-9. PubMed ID: 17853311
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
[TBL] [Abstract][Full Text] [Related]
6. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.
Carlin CS; Feldman SR; Krueger JG; Menter A; Krueger GG
J Am Acad Dermatol; 2004 Jun; 50(6):859-66. PubMed ID: 15153885
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
8. Current concepts and review of alefacept in the treatment of psoriasis.
Krueger GG
Dermatol Clin; 2004 Oct; 22(4):407-26, viii. PubMed ID: 15450337
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system.
GREINER RA; Braathen LR
Eur J Dermatol; 2009; 19(5):494-9. PubMed ID: 19502153
[TBL] [Abstract][Full Text] [Related]
10. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.
Simpson JF; Yelverton CB; Balkrishnan R; Fleischer A; Lide W; Feldman SR
Manag Care Interface; 2006 Jun; 19(6):39-43. PubMed ID: 16892660
[TBL] [Abstract][Full Text] [Related]
11. Management and costs of severe psoriasis: the role of new biologics.
Feldman SR; Pearce DJ
Expert Rev Pharmacoecon Outcomes Res; 2004 Oct; 4(5):573-9. PubMed ID: 19807550
[TBL] [Abstract][Full Text] [Related]
12. Alefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical use.
Korman NJ; Moul DK
Semin Cutan Med Surg; 2005 Mar; 24(1):10-8. PubMed ID: 15900794
[TBL] [Abstract][Full Text] [Related]
13. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
14. The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy.
Menter A
J Cutan Med Surg; 2004 Dec; 8 Suppl 2():20-5. PubMed ID: 15668752
[TBL] [Abstract][Full Text] [Related]
15. Phototherapy, psoriasis, and the age of biologics.
Richard EG; Hönigsmann H
Photodermatol Photoimmunol Photomed; 2014 Feb; 30(1):3-7. PubMed ID: 24313462
[TBL] [Abstract][Full Text] [Related]
16. Immunotargeting in the management of psoriasis.
Kaffenberger BH; Kaffenberger TM; Wong HK
Immunotargets Ther; 2013; 2():51-60. PubMed ID: 27471688
[TBL] [Abstract][Full Text] [Related]
17. Biologics in dermatology: an integrated review.
Sehgal VN; Pandhi D; Khurana A
Indian J Dermatol; 2014 Sep; 59(5):425-41. PubMed ID: 25284845
[TBL] [Abstract][Full Text] [Related]
18. Treatment of psoriasis with intramuscular alefacept.
Ritchlin CT
Curr Rheumatol Rep; 2004 Aug; 6(4):290-1. PubMed ID: 15251079
[No Abstract] [Full Text] [Related]
19. Alefacept for psoriasis: promising drug, open questions.
Naldi L
Arch Dermatol; 2002 Sep; 138(9):1238-40. PubMed ID: 12224990
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
